Title: Chairman & CEO
Workplace: Incyte
Alma Mater: ESSEC Business School
Boards: Incyte, PhRMA
Q&A: Favorite thing about Delaware? “Incyte has called Delaware home for over 20 years. What makes Delaware truly unique is its vibrant and diverse business community that – even as it grows – remains close knit. Over the years, the Delaware community and its local leaders have meaningfully embraced our work at Incyte, which has helped facilitate our continued growth.”
What was your first job? “I sold French wine in San Francisco in 1982.”
Best advice for your younger self? “Find something you love to do — and are good at doing — and make that your ambition.”
Taking the helm of Incyte in 2014 after a career at pharmaceutical giant Novartis, Hervé Hoppenot has led the Wilmington-based drug development company to new heights. Hoppenot has overseen tremendous growth at Incyte, from building upon Incyte’s billion-dollar drug Jakafi®, the approval of Opzelura®, the first drug approved to treat vitiligo and the evolution of Incyte’s presence in the oncology sector with the recent approval of Niktimvo™ for chronic graft-versus-host disease. Expanding on the company’s success to-date, Incyte is continuing to invest heavily to grow product development across its pipeline. The company’s annual revenue has grown nearly 600% since Hoppenot took over, and it has committed to supplement its Delaware headquarters, recently purchasing two downtown Wilmington buildings that will house an estimated 400 employees.
